The Effects of PXR Activation on Hepatic Fat Content

University of Oulu16 enrolled

Overview

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

RifampicinDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers * Body mass index (BMI) 18.5-25 kg/m2 Exclusion Criteria: * Systolic blood pressure over 150 mmHg * Any continuous medication (hormonal intrauterine device is permitted) * Any significant medical condition * Insensitivity to rifampicin * Pregnancy and lactation * Previous difficult venipuncture * Alcohol and medicine abuse and drug use * Participation to any other pharmaceutical trial within on month of screening * Claustrophobia * Metal and other implants which are contraindications to MRI

Locations (1)

Oulu University Hospital

Oulu, Finland

Outcomes

Primary Outcomes

Hepatic fat fraction

Time frame: Day 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.